|Bid||0.00 x 1100|
|Ask||27.80 x 2900|
|Day's Range||16.32 - 17.22|
|52 Week Range||11.95 - 26.10|
|Beta (3Y Monthly)||-0.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AMAG inks a deal to buy Perosphere Pharmaceuticals, which will add the latter's investigational candidate, ciraparantag, to its portfolio.
Does the December share price for AMAG Pharmaceuticals Inc (NASDAQ:AMAG) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by estimating the company’s future cash flows and Read More...
AMAG reports wider than expected loss in the third quarter of 2018. The company completed the sale of Cord Blood Registry in August 2018.
The company's third-quarter financials did little to inspire confidence that its sales can withstand the launch of generic competition.
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of 0.00% and 3.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Waltham, Massachusetts-based company said it had profit of 89 cents. Losses, adjusted for one-time gains and costs, were 77 cents per share. The results met Wall Street expectations. ...
The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals
AMAG Pharmaceuticals (AMAG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to AMAG Pharmaceuticals (AMAG) stock based on the movements in the options market lately.
In Q2 2018, partner Amag Pharmaceuticals (AMAG) reported revenues of $105.2 million for Makena, which is a year-over-year (or YoY) rise of 2.43%. According to Antares Pharma’s Q2 2018 conference call, this growth was driven mainly by the increased overall uptake of the product coupled with the launch of the Makena auto injector in the US market in March 2018. As per AMAG Pharmaceuticals’ estimates based on distributor dispensing data and physician market research data from its investor presentation, Makena accounted for a 51% share of the total market for preventing pre-term birth in at-risk women.
In H1 2018, Antares Pharma (ATRS) reported revenues of $26.86 million, which was a year-over-year (or YoY) rise of 6%. The revenue growth was mainly driven by a 27% YoY rise in product sales, which reached $22.04 million in H1 2018. Wall Street analysts expect Antares Pharma to report revenues of $59.56 million in fiscal 2018, which is a YoY rise of 9.25%.
AMAG acquires global rights to develop/market DIF from Velo Bio to boost its maternal health portfolio. The candidate is under assessment for treating severe preeclampsia in pregnant women.
AMAG Pharmaceuticals (AMAG) needs investors to pay close attention to the stock based on moves in the options market lately.
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -257.14% and -6.90%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 58 cents. Losses, adjusted to account for discontinued operations, were 75 cents per share. The results fell short of ...
Moody's Investors Service ("Moody's") assigned a B3 Corporate Family Rating (CFR) to GI Chill Acquisition LLC (doing business as California Cryobank Life Sciences) At the same time, Moody's assigned a B3-PD Probability of Default Rating (PDR) and a B2 rating to the company's new first lien senior secured term loan and revolver. Proceeds from the debt issuance, along with equity and a new second lien term loan (not rated), will be used in part to fund the acquisition and combination of California Cryobank and Cord Blood Registry by private equity firm, GI Partners. GI Chill's B3 Corporate Family Rating reflects Moody's view that the company will operate with high debt/EBITDA of more than 8.5 times on a GAAP basis (more than 6.5 times if adjusting for deferred revenues related to pre-paid subscriptions) over the next 12-18 months.